A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations...

Descripción completa

Detalles Bibliográficos
Autores principales: Mocroft, A., Reiss, P., Rakhmanova, A., Banhegyi, D., Phillips, A. N., De Wit, S., Ristola, M., Lundgren, J. D., Grarup, J., Kirk, O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103996/
https://www.ncbi.nlm.nih.gov/pubmed/24902520
http://dx.doi.org/10.1007/s15010-014-0630-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103996/
https://www.ncbi.nlm.nih.gov/pubmed/24902520
http://dx.doi.org/10.1007/s15010-014-0630-4

Ejemplares similares